A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- Acronyms RSV OA=ADJ=012
- Sponsors GSK
Most Recent Events
- 08 Apr 2025 Planned number of patients changed from 12000 to 15500.
- 06 Aug 2024 New trial record
- 05 Aug 2024 Status changed from not yet recruiting to recruiting.